Up a level |
Ramanan, AV, Dick, AD, Jones, AP, McKay, A, Williamson, PR ORCID: 0000-0001-9802-6636, Compeyrot-Lacassagne, S, Hardwick, B, Hickey, H, Hughes, D, Woo, P et al (show 3 more authors)
(2016)
ADALIMUMAB IN COMBINATION WITH METHOTREXATE FOR THE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS ASSOCIATED UVEITIS: THE SYCAMORE TRIAL.
.
Horton, S, Jones, AP, Guly, CM, Hardwick, B, Beresford, MW ORCID: 0000-0002-5400-9911, Lee, RWJ, Dick, AD and Ramanan, AV
(2019)
Adalimumab in juvenile-idiopathic arthritis-associated uveitis (JIA-U): 5-year follow-up of the Bristol participants of the SYCAMORE trial.
American journal of ophthalmology, 207.
pp. 170-174.
Ramanan, AV, Dick, AD, Jones, AP, McKay, A ORCID: 0000-0003-1312-8911, Williamson, PR ORCID: 0000-0001-9802-6636, Compeyrot-Lacassagne, S, Hardwick, B, Hickey, H ORCID: 0000-0003-0467-0362, Hughes, D ORCID: 0000-0001-8247-7459, Woo, P et al (show 4 more authors)
(2017)
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.
New England Journal of Medicine, 376 (17).
pp. 1637-1646.
Ramanan, AV, Hampson, LV, Lythgoe, H, Jones, AP, Hardwick, B, Hind, H, Jacobs, B, Vasileiou, D, Wadsworth, I, Ambrose, N et al (show 11 more authors)
(2019)
Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO.
PLOS ONE, 14 (6).
e0215739-.